<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'><collection><source>PubTator</source><date></date><key>BioC.key</key><document><id>8294995</id><passage><infon key="name_3">surname:Sun;given-names:Rui</infon><infon key="name_2">surname:Zhou;given-names:Yue</infon><infon key="name_1">surname:Li;given-names:Fengfei</infon><infon key="name_0">surname:Yuan;given-names:Lu</infon><infon key="year">2021</infon><infon key="article-id_doi">10.1155/2021/5524313</infon><infon key="type">front</infon><infon key="elocation-id">5524313</infon><infon key="volume">2021</infon><infon key="license">This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</infon><infon key="section_type">TITLE</infon><infon key="name_9">surname:Ma;given-names:Jianhua</infon><infon key="name_8">surname:Wu;given-names:Jindan</infon><infon key="name_7">surname:Dai;given-names:Lu</infon><infon key="name_6">surname:Tang;given-names:Yajuan</infon><infon key="name_5">surname:Zhang;given-names:Qing</infon><infon key="name_4">surname:Gao;given-names:Gu</infon><infon key="article-id_pmc">8294995</infon><infon key="article-id_pmid">34337072</infon><offset>0</offset><text>Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial</text><annotation id="7578"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="93" length="7" /><text>Insulin</text></annotation><annotation id="7579"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="63" length="15" /><text>Type 2 Diabetic</text></annotation><annotation id="7581"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="79" length="8" /><text>Patients</text></annotation><annotation id="7582"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="8" length="7" /><text>Glucose</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>141</offset><text>To observe whether different insulin glargine titration algorithms based on fasting blood glucose (FBG) levels lead to different glycaemic variations (GVs) in type 2 diabetes (T2D) patients, a prospective, randomized, single-centre, comparative, three-arm parallel-group, open-label, treat-to-target, 24-week study was performed. A total of 71 uncontrolled T2D patients were recruited and randomized 1 : 3 : 3 into Groups 1, 2, and 3 (insulin titration goals of FBG &lt;= 5.6, &lt;=6.1, and &lt;=7.0) for this study. The initiated insulin glargine dose was recommended at 0.2 U/kg/day and was then titrated following the FBG target. Patients were subjected to two 3-day continuous glucose monitoring (CGM) at baseline and the endpoint, wherein the CGM data were analysed, and the study's primary endpoint was the difference in 24 hrs mean amplitude of glycaemic excursion (MAGE) among the three groups. We observed that patients in the three groups had similar MAGE levels at the endpoint; however, Group 2 achieved a significant decrease in the MAGE level from baseline to the endpoint as compared to Groups 1 and 3 (all p &lt; 0.05). We also observed that these patients had significant glycated haemoglobin A1c (HbA1c) value improvements as compared to the other two groups (all p &lt; 0.05). Therefore, choosing an FBG level of 6.1 mmol/L as an insulin titration target provided significant GVs and HbA1c value improvements in T2D patients. Moreover, our data indicated that an FBG of 6.1 mmol/L could possibly be an insulin glargine titration target in T2D patients.</text><annotation id="7583"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="576" length="7" /><text>insulin</text></annotation><annotation id="7584"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="1475" length="7" /><text>insulin</text></annotation><annotation id="7585"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="1647" length="7" /><text>insulin</text></annotation><annotation id="7586"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="663" length="7" /><text>insulin</text></annotation><annotation id="7587"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="170" length="7" /><text>insulin</text></annotation><annotation id="7588"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1293" length="8" /><text>patients</text></annotation><annotation id="7589"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="317" length="3" /><text>T2D</text></annotation><annotation id="7592"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="765" length="8" /><text>Patients</text></annotation><annotation id="7593"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="300" length="15" /><text>type 2 diabetes</text></annotation><annotation id="7594"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1052" length="8" /><text>patients</text></annotation><annotation id="7595"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="322" length="8" /><text>patients</text></annotation><annotation id="7596"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1688" length="8" /><text>patients</text></annotation><annotation id="7598"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="231" length="7" /><text>glucose</text></annotation><annotation id="7599"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="498" length="3" /><text>T2D</text></annotation><annotation id="7600"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="1557" length="3" /><text>T2D</text></annotation><annotation id="7601"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1561" length="8" /><text>patients</text></annotation><annotation id="7602"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="813" length="7" /><text>glucose</text></annotation><annotation id="7603"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="1684" length="3" /><text>T2D</text></annotation><annotation id="7604"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="502" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1723</offset><text>1. Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1739</offset><text>Globally, China is among the top 10 countries for the highest number of diabetes patients (114 million), as well as total healthcare expenditure on diabetes. Microvascular and macrovascular complication incidences, in particular, depend largely on the glycaemic control of diabetic patients. Therefore, tasks for maintaining glucose control in these patients remain a focus of research.</text><annotation id="7605"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="2089" length="8" /><text>patients</text></annotation><annotation id="7606"><infon key="identifier">OMIM:603933</infon><infon key="type">Disease</infon><location offset="1897" length="44" /><text>Microvascular and macrovascular complication</text></annotation><annotation id="7607"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1811" length="8" /><text>diabetes</text></annotation><annotation id="7608"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="2064" length="7" /><text>glucose</text></annotation><annotation id="7609"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="1887" length="8" /><text>diabetes</text></annotation><annotation id="7610"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="2012" length="8" /><text>diabetic</text></annotation><annotation id="7611"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="2021" length="8" /><text>patients</text></annotation><annotation id="7612"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1820" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2126</offset><text>A study conducted in China reported that 67.5% of Chinese type 2 diabetes (T2D) patients were on insulin therapy, but only 15% of them had glycated haemoglobin A1c (HbA1c) levels of less than 7.0%. Among the blood glucose indices, HbA1c is a very useful parameter for reflecting 2-3 months of mean glucose control. A previous study demonstrated that a reduction in HbA1c value in diabetes patients was associated with a decrease in the risk of microvascular and macrovascular complications. However, it should be noted that HbA1c does not necessarily refer to daily glucose variations (GVs), since studies have found that patients with different GVs may have similar HbA1c values. GV, more specifically, is a potential risk factor for oxidative stress, endothelial dysfunction, and inflammation, all contributing to vascular endothelial cell damage. Importantly, studies have already demonstrated positive correlations between GV and diabetic micro- and macrovascular complications. Therefore, the role of HbA1c and GVs should be highlighted in T2D to decrease diabetic complication incidences. In response to this, continuous glucose monitoring (CGM), which continuously provides glucose readings at 5-minute intervals for several days, may be a potential tool for assessing GVs in T2D patients.</text><annotation id="7613"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="2223" length="7" /><text>insulin</text></annotation><annotation id="7614"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="2748" length="8" /><text>patients</text></annotation><annotation id="7615"><infon key="identifier">MESH:D001786</infon><infon key="type">Chemical</infon><location offset="2334" length="13" /><text>blood glucose</text></annotation><annotation id="7616"><infon key="identifier">MESH:D007249</infon><infon key="type">Disease</infon><location offset="2908" length="12" /><text>inflammation</text></annotation><annotation id="7617"><infon key="identifier">MESH:D014652</infon><infon key="type">Disease</infon><location offset="2879" length="23" /><text>endothelial dysfunction</text></annotation><annotation id="7618"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="2506" length="8" /><text>diabetes</text></annotation><annotation id="7619"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="2201" length="3" /><text>T2D</text></annotation><annotation id="7620"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="3171" length="3" /><text>T2D</text></annotation><annotation id="7621"><infon key="type">Disease</infon><location offset="3053" length="2" /><text>GV</text></annotation><annotation id="7623"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3413" length="8" /><text>patients</text></annotation><annotation id="7624"><infon key="identifier">MESH:D048909</infon><infon key="type">Disease</infon><location offset="3187" length="21" /><text>diabetic complication</text></annotation><annotation id="7625"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="2206" length="8" /><text>patients</text></annotation><annotation id="7626"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="3409" length="3" /><text>T2D</text></annotation><annotation id="7627"><infon key="identifier">MESH:D048909</infon><infon key="type">Disease</infon><location offset="3060" length="47" /><text>diabetic micro- and macrovascular complications</text></annotation><annotation id="7628"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="3253" length="7" /><text>glucose</text></annotation><annotation id="7629"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="3307" length="7" /><text>glucose</text></annotation><annotation id="7630"><infon key="type">Disease</infon><location offset="2807" length="2" /><text>GV</text></annotation><annotation id="7631"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="2515" length="8" /><text>patients</text></annotation><annotation id="7632"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="2424" length="7" /><text>glucose</text></annotation><annotation id="7633"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="2692" length="7" /><text>glucose</text></annotation><annotation id="7634"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="2184" length="15" /><text>type 2 diabetes</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3431</offset><text>Insulin glargine (Lantus ) is a long-acting insulin analogue that provides the advantage of a once-daily dosage to maintain glycaemic control in T2D patients. Interestingly, its initiation has been verified as a successful strategy for uncontrolled T2D that is unresolved even with 1-3 oral antidiabetic drugs (OADs). Furthermore, insulin glargine exhibits potential efficacy and safety in combination with different glucose-lowering agents. It causes significant improvements in HbA1c values and low hypoglycaemia incidences.</text><annotation id="7635"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="3762" length="7" /><text>insulin</text></annotation><annotation id="7636"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="3475" length="7" /><text>insulin</text></annotation><annotation id="7637"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="3431" length="7" /><text>Insulin</text></annotation><annotation id="7638"><infon key="type">Disease</infon><location offset="3932" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7640"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="3576" length="3" /><text>T2D</text></annotation><annotation id="7641"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="3680" length="3" /><text>T2D</text></annotation><annotation id="7643"><infon key="identifier">MESH:D000069036</infon><infon key="type">Chemical</infon><location offset="3449" length="6" /><text>Lantus</text></annotation><annotation id="7644"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="3580" length="8" /><text>patients</text></annotation><annotation id="7645"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="3717" length="23" /><text>oral antidiabetic drugs</text></annotation><annotation id="7646"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="3742" length="4" /><text>OADs</text></annotation><annotation id="7647"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="3848" length="7" /><text>glucose</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3959</offset><text>In clinical practice, physicians often titrate the insulin glargine dosage according to the fasting blood glucose (FBG) level, since appropriate day-to-day blood glucose goals may play an important role in achieving glycaemic control in patients receiving insulin therapy. It should also be noted that there was a wide variation between the FBG values to achieve the recommended HbA1c targets from various organizations. For example, FBG &lt;= 5.6, 6.1, and 7.0 mmol/L were recommended as optional glucose control goals by the international and domestic guidelines. However, evidence of whether the optimization of insulin glargine titration targets is beneficial in GV of T2D patients is largely unknown.</text><annotation id="7649"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="4010" length="7" /><text>insulin</text></annotation><annotation id="7650"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="4215" length="7" /><text>insulin</text></annotation><annotation id="7651"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="4571" length="7" /><text>insulin</text></annotation><annotation id="7652"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4196" length="8" /><text>patients</text></annotation><annotation id="7653"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="4629" length="3" /><text>T2D</text></annotation><annotation id="7654"><infon key="identifier">MESH:D000069036</infon><infon key="type">Chemical</infon><location offset="4018" length="8" /><text>glargine</text></annotation><annotation id="7655"><infon key="identifier">MESH:D001786</infon><infon key="type">Chemical</infon><location offset="4059" length="13" /><text>blood glucose</text></annotation><annotation id="7656"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="4454" length="7" /><text>glucose</text></annotation><annotation id="7657"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="4633" length="8" /><text>patients</text></annotation><annotation id="7658"><infon key="identifier">MESH:D000069036</infon><infon key="type">Chemical</infon><location offset="4579" length="8" /><text>glargine</text></annotation><annotation id="7659"><infon key="identifier">MESH:D001786</infon><infon key="type">Chemical</infon><location offset="4115" length="13" /><text>blood glucose</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4665</offset><text>Therefore, we performed a prospective study to determine whether different FBG targets lead to different GV values in the Chinese T2D population who were receiving insulin glargine analogue.</text><annotation id="7660"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="4795" length="3" /><text>T2D</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4856</offset><text>2. Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4881</offset><text>2.1. Study Design</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4899</offset><text>This was a prospective, randomized, single-centre, comparative, three-arm parallel-group, open-label, treat-to-target study. The study protocol and patient consent forms were approved by the Institutional Ethical Committee of Nanjing First Hospital, Nanjing Medical University, and all procedures performed were in accordance with the ethical standards of Nanjing First Hospital and the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all the patients for recruitment in the study, and this study was registered with ClinicalTrials.gov identifier: NCT02545842.</text><annotation id="7661"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5379" length="8" /><text>patients</text></annotation><annotation id="7662"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5047" length="7" /><text>patient</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5497</offset><text>From October 2016 to April 2018, T2D patients who presented with insufficiently controlled diabetes for at least 3 months were enrolled as outpatients in the Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, China. The inclusion criteria were as follows: (1) willingness to participate in the study with a signed informed consent; (2) aged between 18 and 65 years; (3) T2D insufficiently controlled by 1-3 OADs with a stable dose for at least 3 months: (3a) if on 1 OAD, provided with the following doses (submaximum (half dose above) to maximum dose (for details, refer to the package inserts)) or the maximum tolerated dose allowed in the package insert, and (3b) if on 2-3 OADs, any dose was acceptable; (4) HbA1c value &gt; 7% but &lt;=10.5%; (5) FBG level &gt; 7 mmol/L (biochemistry result); (6) body mass index &gt;= 20 kg/m2 but &lt;=40 kg/m2; (7) diabetes duration &gt;= 1 year; (8) availability of physician prescription and patient's consent to start insulin glargine treatment; and (9) willing to undergo CGM. On the contrary, the exclusion criteria were as follows: (1) type 1 diabetes patients; (2) patients with acute diabetic complications (including unexplained severe hypoglycaemia in the last 6 months); (3) previous treatment with insulin for more than 1 month in the last 1 year, or treatment with insulin in the 3 months before the screening; (4) known hypoglycaemia unawareness or recurrent hypoglycaemia; (5) hypersensitivity to study drug or its excipients; (6) any clinically significant acute major organ or systemic disease, or any other situation which might be difficult for the 24 weeks follow-up, as judged by the investigator; (7) pregnant or breastfeeding women; (8) any mental disorders, lack of self-control, or inability to express accurately; and (9) involved in another clinical trial simultaneously or within 1 month before the start of the trial.</text><annotation id="7663"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="6829" length="7" /><text>insulin</text></annotation><annotation id="7664"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="6761" length="7" /><text>insulin</text></annotation><annotation id="7665"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="6472" length="7" /><text>insulin</text></annotation><annotation id="7666"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6609" length="8" /><text>patients</text></annotation><annotation id="7667"><infon key="identifier">MESH:D003922</infon><infon key="type">Disease</infon><location offset="6593" length="15" /><text>type 1 diabetes</text></annotation><annotation id="7668"><infon key="identifier">MESH:D018458</infon><infon key="type">Disease</infon><location offset="6885" length="25" /><text>hypoglycaemia unawareness</text></annotation><annotation id="7669"><infon key="identifier">MESH:D048909</infon><infon key="type">Disease</infon><location offset="6643" length="22" /><text>diabetic complications</text></annotation><annotation id="7670"><infon key="identifier">MESH:D000069036</infon><infon key="type">Chemical</infon><location offset="6480" length="8" /><text>glargine</text></annotation><annotation id="7671"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="6204" length="4" /><text>OADs</text></annotation><annotation id="7672"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5534" length="8" /><text>patients</text></annotation><annotation id="7673"><infon key="identifier">MESH:D001523</infon><infon key="type">Disease</infon><location offset="7215" length="16" /><text>mental disorders</text></annotation><annotation id="7675"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="6369" length="8" /><text>diabetes</text></annotation><annotation id="7676"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="5934" length="4" /><text>OADs</text></annotation><annotation id="7677"><infon key="type">Disease</infon><location offset="6696" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7678"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="5897" length="3" /><text>T2D</text></annotation><annotation id="7679"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7200" length="5" /><text>women</text></annotation><annotation id="7681"><infon key="type">Disease</infon><location offset="6924" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7682"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6445" length="7" /><text>patient</text></annotation><annotation id="7683"><infon key="type">Disease</infon><location offset="5994" length="3" /><text>OAD</text></annotation><annotation id="7684"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="5530" length="3" /><text>T2D</text></annotation><annotation id="7685"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6623" length="8" /><text>patients</text></annotation><annotation id="7686"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="5588" length="8" /><text>diabetes</text></annotation><annotation id="7688"><infon key="identifier">MESH:D004342</infon><infon key="type">Disease</infon><location offset="6943" length="16" /><text>hypersensitivity</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7412</offset><text>Following the inclusion of participants, the treatment code list was generated centrally, wherein treatments were allocated to each patient via a centralized system (interactive voice response system; IVRS/interactive web-response system; IWRS), and the randomization list was generated by a statistician who liaised with the IVRS/IWRS service. The patients were then randomized at a 1 : 3 : 3 ratio into one of the three groups: Group 1 (FBG level target &lt;= 5.6 mmol/L), Group 2 (FBG level target &lt;= 6.1 mmol/L), and Group 3 (FBG level target &lt;= 7.0 mmol/L) at Visit 2 (week 0).</text><annotation id="7689"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7939" length="3" /><text>FBG</text></annotation><annotation id="7690"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7544" length="7" /><text>patient</text></annotation><annotation id="7691"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7761" length="8" /><text>patients</text></annotation><annotation id="7692"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7851" length="3" /><text>FBG</text></annotation><annotation id="7693"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7439" length="12" /><text>participants</text></annotation><annotation id="7694"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="7893" length="3" /><text>FBG</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8009</offset><text>The study included a 0- to 2-week screening period and a 24-week treatment period, with 18 visits occurring as the study schedule. The study flowchart is further illustrated in detail in Figure 1. In brief, prior to the study, all patients were provided with instructions for measuring FBG levels and administering insulin glargine. The FBG level was recorded daily by patients before breakfast, and insulin glargine was self-administered once daily at bedtime (from 21:00 to 23:00) by subcutaneous injection into the abdomen (preferred route) using a SoloSTAR  disposable pen. Moreover, the initial insulin glargine dose was recommended at 0.2 U/kg/day, with a wave of 4 U, as permitted according to the patient's clinical condition by the investigator. The investigator would then titrate the insulin dosage according to the lowest value of the last three consecutive FBG values prior to each visit. The detailed insulin dose titration algorithm is presented in Table 1. Additionally, the insulin injection time and OADs taken by patients at baseline remained unchanged and were continued at a fixed and stable dose during the study.</text><annotation id="7695"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="8924" length="7" /><text>insulin</text></annotation><annotation id="7696"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="9000" length="7" /><text>insulin</text></annotation><annotation id="7697"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="8804" length="7" /><text>insulin</text></annotation><annotation id="7698"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="8609" length="7" /><text>insulin</text></annotation><annotation id="7699"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="8409" length="7" /><text>insulin</text></annotation><annotation id="7700"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="8324" length="7" /><text>insulin</text></annotation><annotation id="7701"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="8879" length="3" /><text>FBG</text></annotation><annotation id="7703"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="8295" length="3" /><text>FBG</text></annotation><annotation id="7705"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="8346" length="3" /><text>FBG</text></annotation><annotation id="7707"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8378" length="8" /><text>patients</text></annotation><annotation id="7709"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8240" length="8" /><text>patients</text></annotation><annotation id="7710"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9041" length="8" /><text>patients</text></annotation><annotation id="7711"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8714" length="7" /><text>patient</text></annotation><annotation id="7712"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9027" length="4" /><text>OADs</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9150</offset><text>2.2. Efficacy Measurements</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>9177</offset><text>2.2.1. HbA1c</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9190</offset><text>Fasting serum samples were collected and sent to the ICON Laboratory (Shanghai, China) for HbA1c measurements at Visits 1 and 18, respectively.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>9334</offset><text>2.2.2. Fasting Blood Glucose</text><annotation id="7713"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="9341" length="21" /><text>Fasting Blood Glucose</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9363</offset><text>Finger-striped blood glucose monitoring was carried out using the sponsor-provided glucose meter, which was performed by the recruited participants at home after at least 8 hours of fasting. Patients were instructed to report their FBG levels for at least 3 consecutive days of the visit week and at least 2 consecutive days of the visit-free week.</text><annotation id="7714"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9554" length="8" /><text>Patients</text></annotation><annotation id="7715"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="9446" length="7" /><text>glucose</text></annotation><annotation id="7716"><infon key="identifier">MESH:D001786</infon><infon key="type">Chemical</infon><location offset="9378" length="13" /><text>blood glucose</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>9712</offset><text>2.2.3. CGM</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9723</offset><text>All recruited patients were subjected to a two-time, 3-day, retrospective CGM (Sof-sensor, CGMS-Gold, Medtronic Incorporated, Northridge, USA) at 3 days of Visits 2 and 18, as described previously. During the two-time CGM period, patients were instructed to maintain moderate physical activity and have breakfast, lunch, and dinner at 07:00, 11:00, and 17:00, respectively, with a total daily caloric intake of 25 kcal/kg/day. The percentages of carbohydrates, proteins, and fats were 55%, 17%, and 28%, respectively. After the CGM data collection, the mean amplitude of glycaemic excursion (MAGE) was calculated manually for each patient by measuring the arithmetic mean of the ascending and descending excursions between consecutive peaks and nadirs for the same 24 hr period, wherein only absolute excursion values &gt; 1 standard deviation (SD) were considered, as previously described. In addition, other glucose indicators, such as the 24 hr mean glucose concentration (MG), coefficient of variation (CV%), 24 hr standard deviation of the MG (SD), incremental area under the curve (AUC) of plasma glucose &gt; 10.0 mmol/L, and the incremental area over the curve (AOC) &lt; 3.9 mmol/L, were also recorded.</text><annotation id="7717"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="10630" length="7" /><text>glucose</text></annotation><annotation id="7718"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="10354" length="7" /><text>patient</text></annotation><annotation id="7719"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="10823" length="7" /><text>glucose</text></annotation><annotation id="7720"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="10673" length="7" /><text>glucose</text></annotation><annotation id="7721"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9737" length="8" /><text>patients</text></annotation><annotation id="7722"><infon key="identifier">MESH:D002241</infon><infon key="type">Chemical</infon><location offset="10169" length="13" /><text>carbohydrates</text></annotation><annotation id="7723"><infon key="identifier">MESH:D005223</infon><infon key="type">Chemical</infon><location offset="10198" length="4" /><text>fats</text></annotation><annotation id="7724"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="9953" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10940</offset><text>2.3. Outcomes</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10954</offset><text>The primary outcome of this study was to identify whether different insulin glargine titration algorithms based on different FBG levels lead to different MAGE in T2D patients. The second outcome was the differences in HbA1c values, MG, SD, CV%, AUC values, and AOC values of the patients among the three groups.</text><annotation id="7725"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="11022" length="7" /><text>insulin</text></annotation><annotation id="7726"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11120" length="8" /><text>patients</text></annotation><annotation id="7727"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="11116" length="3" /><text>T2D</text></annotation><annotation id="7728"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="11233" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>11266</offset><text>2.4. Statistical Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11292</offset><text>The analyses were performed using the SPSS 22.0 (SPSS, Science, Chicago, USA) statistical package. All variables were tested for the normal distribution of data and are presented as mean +- SD or as median (25th percentile; 75th percentile), based on the data's normal distribution. Parameters that did not fulfill a normal distribution were mathematically transformed to improve symmetry for subsequent analyses. One-way ANOVA, T-test, nonparametric tests, and chi-square test had been used for difference analysis among groups, respectively. All comparisons were 2-sided, and statistical significance for all analyses was set at p &lt; 0.05.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>11933</offset><text>3. Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11944</offset><text>3.1. Demographic Characteristics</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11977</offset><text>A total of 133 participants with T2D were assessed for eligibility, and 62 participants did not meet the inclusion criteria. Thus, the CGM data of 71 participants were collected and analysed at the endpoint (Figure 2).</text><annotation id="7729"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="12010" length="3" /><text>T2D</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12196</offset><text>There were no differences in the demographic characteristics of the recruited participants among the three groups (Table 2). The number of OADs in each group is further described in Table 2. There were no significant differences in the ratio of OADs among the three groups.</text><annotation id="7730"><infon key="identifier">MESH:D000092582</infon><infon key="type">Disease</infon><location offset="12335" length="4" /><text>OADs</text></annotation><annotation id="7731"><infon key="identifier">MESH:D000092582</infon><infon key="type">Disease</infon><location offset="12441" length="4" /><text>OADs</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12470</offset><text>The FBG levels at baseline and the endpoint are shown in Table 3, wherein all patients among the three groups achieved significant improvements from baseline to endpoint (all p &lt; 0.01). At baseline, FBG levels did not differ between the groups; however, the FBG levels in Groups 1 and 2 were significantly lower than those in Group 3 at the endpoint. After 24 weeks, 70.0%, 88.5%, and 80.0% of patients in Groups 1, 2, and 3, respectively, had FBG values within their predefined target range according to a preplanned titration strategy based on the lowest value of the last three consecutive FBG values.</text><annotation id="7732"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="12914" length="3" /><text>FBG</text></annotation><annotation id="7733"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="13063" length="3" /><text>FBG</text></annotation><annotation id="7734"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="12728" length="3" /><text>FBG</text></annotation><annotation id="7735"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="12669" length="3" /><text>FBG</text></annotation><annotation id="7736"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12548" length="8" /><text>patients</text></annotation><annotation id="7737"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="12864" length="8" /><text>patients</text></annotation><annotation id="7738"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="12474" length="3" /><text>FBG</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13075</offset><text>To assess the effects of insulin glargine on glycaemic control in this study, we observed changes in HbA1c values from baseline to the endpoint. As Table 4 shows, all patients among the three groups achieved significant improvement in HbA1c values from baseline to endpoint (all p &lt; 0.01). Importantly, the HbA1c level change percentage in Group 2 was significantly higher than that in Groups 1 and 3 (all p &lt; 0.05). Furthermore, we observed that the percentage of patients with HbA1c levels less than 6.5% was numerically higher in Group 2 than in the other two groups (10.0%, 30.8%, and 17.1%, respectively), but the difference was not significantly different from either Group 1 or Group 3 (p &gt; 0.05).</text><annotation id="7739"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="13100" length="7" /><text>insulin</text></annotation><annotation id="7740"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="13540" length="8" /><text>patients</text></annotation><annotation id="7742"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="13242" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>13780</offset><text>3.2. CGM Profiles</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13798</offset><text>CGM data showed that the MG values of the recruited participants in all groups significantly improved upon comparing baseline to the endpoint values. In accordance with our HbA1c outcomes, our data showed that the MG value in Group 2 was significantly lower than that in Group 3 (p &lt; 0.01) and was insignificantly reduced as compared to Group 1 (p &gt; 0.05).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14155</offset><text>We then analysed the GV profiles of patients among the three groups. Our data indicated that patients had similar MAGE values at the endpoint, with the exception of patients in Group 2, showing a significant SD value reduction as compared to Group 3. However, we also observed that SD and MAGE value changes in Group 2 decreased from baseline to the endpoint as compared to both Groups 1 and 3 (p &lt; 0.01, respectively) (Table 5).</text><annotation id="7743"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14191" length="8" /><text>patients</text></annotation><annotation id="7744"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14248" length="8" /><text>patients</text></annotation><annotation id="7745"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14320" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14585</offset><text>Furthermore, CGM data showed that the hyperglycaemia (AUC values &gt; 10 mmol/L) values were insignificantly decreased in Groups 1 and 3, and significant improvement from baseline to the endpoint was observed in Group 2. Although patients had similar hyperglycaemia values between Groups 1 and 3 at the endpoint, we observed a dramatic decrease in hyperglycaemia values at the endpoint in Group 2 as compared to Group 3 (Table 5).</text><annotation id="7746"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="14812" length="8" /><text>patients</text></annotation><annotation id="7747"><infon key="type">Disease</infon><location offset="14833" length="14" /><text>hyperglycaemia</text></annotation><annotation id="7748"><infon key="type">Disease</infon><location offset="14930" length="14" /><text>hyperglycaemia</text></annotation><annotation id="7749"><infon key="type">Disease</infon><location offset="14623" length="14" /><text>hyperglycaemia</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>15015</offset><text>3.3. Safety and Weight Gain</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15043</offset><text>Patients in all three groups had the same hypoglycaemia values (finger-striped blood glucose &lt; 3.9 mmol/L) or symptomatic hypoglycaemia incidences (0 (0, 1.25) vs. 0 (0, 1) vs. 0 (0, 0), p &gt; 0.05). More importantly, our CGM data indicated that the hypoglycaemia (AOC &lt; 3.9 mmol/L) values were similar either at baseline or the endpoint among the three groups (p &gt; 0.05), showing no differences upon making comparisons between baseline and the endpoint, as well as among the three groups (p &gt; 0.05) (Table 5).</text><annotation id="7750"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15043" length="8" /><text>Patients</text></annotation><annotation id="7751"><infon key="type">Disease</infon><location offset="15165" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7752"><infon key="type">Disease</infon><location offset="15291" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7753"><infon key="type">Disease</infon><location offset="15085" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7754"><infon key="identifier">MESH:D001786</infon><infon key="type">Chemical</infon><location offset="15122" length="13" /><text>blood glucose</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15556</offset><text>Moreover, we observed that there was no difference in weight gain from baseline to endpoint among the three groups (p &gt; 0.05). Insulin dose was also found to have had no difference among the three groups at the endpoint (Group 1: 0.3 +- 0.1, Group 2: 0.3 +- 0.1, and Group 3: 0.2 +- 0.1 U/kg, p &gt; 0.05), as well as at each visit (Figure 3).</text><annotation id="7755"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="15683" length="7" /><text>Insulin</text></annotation><annotation id="7756"><infon key="identifier">MESH:D015430</infon><infon key="type">Disease</infon><location offset="15610" length="11" /><text>weight gain</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>15899</offset><text>4. Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>15913</offset><text>This prospective study showed that T2D patients receiving insulin glargine therapy had day-to-day FBG values of less than 6.1 mmol/L, leading to a significant improvement in short-term and long-term glycaemic control. Therefore, the insulin glargine titration target threshold may be an FBG of 6.1 mmol/L in T2D patients, as indicated in our data.</text><annotation id="7757"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="16146" length="7" /><text>insulin</text></annotation><annotation id="7758"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="15971" length="7" /><text>insulin</text></annotation><annotation id="7759"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="15948" length="3" /><text>T2D</text></annotation><annotation id="7760"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="15952" length="8" /><text>patients</text></annotation><annotation id="7761"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="16221" length="3" /><text>T2D</text></annotation><annotation id="7763"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16225" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16265</offset><text>In this study, not all patients achieved the preset FBG goals as assigned, with the ratio between the three groups being similar at 24 weeks. Specifically, the ratio in the BEYOND III was 70.1%, 67.6%, and 79.0% in Groups 1, 2, and 3, respectively. Although most previous studies have employed HbA1c as the primary glycaemic control measure, this only provides an approximate measurement of glucose control, since it does not address acute/short-term GV or hypoglycaemic events. CGM, on the contrary, is a useful tool that helps clinicians and diabetic patients to overcome the limitations of HbA1c in diabetes management. Notably, many CGM parameters were found to reflect GV, such as MAGE, SD, and CV%. As mentioned previously, GV is a risk factor that contributes to the pathogenesis of diabetes micro- and macrovascular complications. Additionally, strict FBG level control using insulin glargine may not lead to further GV improvement T2D in patients. In this prospective study, patients with an FBG level of 5.6 mmol/L as the insulin glargine titration target failed to achieve the largest GV reduction. In contrast, our data showed that T2D patients in Group 2 had insignificant MAGE and SD decreases from baseline to the endpoint, while the MAGE and SD values in those of the other two groups were insignificantly increased. More importantly, we observed a significantly increased change amplification in MAGE and SD values from baseline to the endpoint in Group 2 as compared to either Group 1 or Group 3. However, despite these findings, the mechanism behind the different MAGE and SD change patterns among the three groups was unclear. We consider the reason might be that while hypoglycaemia (AOC &lt; 3.9 mmol/L) values were similar either at baseline or the endpoint among the three groups, hyperglycaemia (AUC &gt;10 mmol/L) was found to be significantly declined in Group 2 from baseline to the endpoint. Thus, glycaemia control in Group 2 was more stable than in the other two groups. Furthermore, although MAGE and SD values in Group 2 decreased significantly from baseline to the endpoint, CV% was conversely increased, which was possibly due to the dramatically decreased MG from baseline to the endpoint.</text><annotation id="7765"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="17297" length="7" /><text>insulin</text></annotation><annotation id="7766"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="17149" length="7" /><text>insulin</text></annotation><annotation id="7767"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="17409" length="3" /><text>T2D</text></annotation><annotation id="7768"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17249" length="8" /><text>patients</text></annotation><annotation id="7769"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="17125" length="3" /><text>FBG</text></annotation><annotation id="7770"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="16656" length="7" /><text>glucose</text></annotation><annotation id="7771"><infon key="type">Disease</infon><location offset="17955" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7772"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="16317" length="3" /><text>FBG</text></annotation><annotation id="7773"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16818" length="8" /><text>patients</text></annotation><annotation id="7775"><infon key="type">Disease</infon><location offset="18067" length="14" /><text>hyperglycaemia</text></annotation><annotation id="7776"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="16809" length="8" /><text>diabetic</text></annotation><annotation id="7777"><infon key="type">Disease</infon><location offset="16722" length="13" /><text>hypoglycaemic</text></annotation><annotation id="7778"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17212" length="8" /><text>patients</text></annotation><annotation id="7779"><infon key="type">Disease</infon><location offset="18186" length="9" /><text>glycaemia</text></annotation><annotation id="7781"><infon key="type">Disease</infon><location offset="16939" length="2" /><text>GV</text></annotation><annotation id="7782"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="17413" length="8" /><text>patients</text></annotation><annotation id="7783"><infon key="identifier">MESH:D048909</infon><infon key="type">Disease</infon><location offset="17055" length="47" /><text>diabetes micro- and macrovascular complications</text></annotation><annotation id="7784"><infon key="type">Disease</infon><location offset="17361" length="2" /><text>GV</text></annotation><annotation id="7785"><infon key="type">Disease</infon><location offset="16716" length="2" /><text>GV</text></annotation><annotation id="7786"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="17205" length="3" /><text>T2D</text></annotation><annotation id="7787"><infon key="type">Disease</infon><location offset="16995" length="2" /><text>GV</text></annotation><annotation id="7788"><infon key="type">Disease</infon><location offset="17190" length="2" /><text>GV</text></annotation><annotation id="7789"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="16288" length="8" /><text>patients</text></annotation><annotation id="7790"><infon key="identifier">MESH:D003920</infon><infon key="type">Disease</infon><location offset="16867" length="8" /><text>diabetes</text></annotation><annotation id="7791"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="17266" length="3" /><text>FBG</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18491</offset><text>A 16-week prospective study conducted in China reported that T2D patients receiving insulin glargine and targeting an FBG of 6.1 mmol/L had nearly a 1.8 mmol/L reduction in MAGE values. In agreement with the previous study, we also used an FBG of 6.1 mmol/L as the insulin titration threshold target, finding a 1.4 mmol/L improvement in the MAGE value (6.2 +- 3.2 to 4.7 +- 2.8 mmol/L) from baseline to the endpoint. However, we did not observe the same change trend in the other two groups, which used FBG levels of 5.6 and 7.0 mmol/L, respectively. As such, we have addressed this as another limitation of this study since we have no data backing up the underlying mechanisms.</text><annotation id="7792"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="18756" length="7" /><text>insulin</text></annotation><annotation id="7793"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="18575" length="7" /><text>insulin</text></annotation><annotation id="7794"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="18556" length="8" /><text>patients</text></annotation><annotation id="7795"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="18552" length="3" /><text>T2D</text></annotation><annotation id="7796"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="18609" length="3" /><text>FBG</text></annotation><annotation id="7798"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="18731" length="3" /><text>FBG</text></annotation><annotation id="7799"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="18994" length="3" /><text>FBG</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19182</offset><text>Based on previous studies, MAGE was considered as the gold standard to reflect GV, while SD is simple and sensitive in reflecting GV. MAGE, in particular, has contributed significantly to decreasing antioxidation capacity as compared to chronic sustained hyperglycaemia in patients with different types of glucose regulation. In fact, CGM-based MAGE has been significantly correlated with urinary 8-iso-prostaglandin F2a levels, IMT, and Gensini score in T2D patients. In relation to this, we further observed that patients receiving insulin glargine with an FBG of 6.1 mmol/L as titration threshold exhibited an SD change from 2.3 +- 1.0 to 1.8 +- 0.9 mmol/L during the 24-week treatment. However, the MAGE and SD values in T2D patients at the endpoint in this study were higher as compared to the recommended values in the Chinese population. Therefore, studies on insulin glargine aimed at reducing MAGE and SD values are warranted in the future.</text><annotation id="7800"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="19716" length="7" /><text>insulin</text></annotation><annotation id="7801"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19697" length="8" /><text>patients</text></annotation><annotation id="7802"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="19579" length="23" /><text>8-iso-prostaglandin F2a</text></annotation><annotation id="7803"><infon key="type">Disease</infon><location offset="19437" length="14" /><text>hyperglycaemia</text></annotation><annotation id="7804"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="19488" length="7" /><text>glucose</text></annotation><annotation id="7805"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="19637" length="3" /><text>T2D</text></annotation><annotation id="7806"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19911" length="8" /><text>patients</text></annotation><annotation id="7807"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19641" length="8" /><text>patients</text></annotation><annotation id="7808"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="19455" length="8" /><text>patients</text></annotation><annotation id="7810"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="19907" length="3" /><text>T2D</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20136</offset><text>A previous study reported that T2D patients receiving OADs with add-on glargine therapy for 16 weeks had their HbA1c levels reduced from 8.35 +- 0.24 to 7.14 +- 0.16%. Similarly, in our study, we observed that T2D patients receiving insulin glargine had a significant reduction in HbA1c value after the 24-week treatment period, with HbA1c values varying from 6.8 +- 0.7 to 7.3 +- 0.8% at the endpoint. Interestingly, in accordance with our outcome regarding the benefits of GV improvement in patients with an FBG of 6.1 mmol/L as the titration target, we also found that patients in Group 2 had a significant HbA1c value reduction as compared to those in Groups 1 and 3, which was in agreement with a previous study reporting that using an FBG of 6.1 mmol/L as the insulin glargine titration target led to significant HbA1c value improvements in T2D patients.</text><annotation id="7811"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="20902" length="7" /><text>insulin</text></annotation><annotation id="7812"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="20369" length="7" /><text>insulin</text></annotation><annotation id="7813"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20987" length="8" /><text>patients</text></annotation><annotation id="7815"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20350" length="8" /><text>patients</text></annotation><annotation id="7816"><infon key="identifier">MESH:D000069036</infon><infon key="type">Chemical</infon><location offset="20207" length="8" /><text>glargine</text></annotation><annotation id="7818"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="20983" length="3" /><text>T2D</text></annotation><annotation id="7819"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20171" length="8" /><text>patients</text></annotation><annotation id="7820"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20629" length="8" /><text>patients</text></annotation><annotation id="7821"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="20708" length="8" /><text>patients</text></annotation><annotation id="7822"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="20346" length="3" /><text>T2D</text></annotation><annotation id="7823"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="20190" length="4" /><text>OADs</text></annotation><annotation id="7824"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="20167" length="3" /><text>T2D</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21001</offset><text>It is logical to see a significant difference in insulin doses among the three groups, due to their varying FBG targets. However, we did not observe any differences among the three groups at Visit 2 and at the endpoint, even during the insulin titration period (from Visit 3 to Visit 17). Another strength of this study was that all recruited participants received a mean insulin dose of 0.3 U/kg at the endpoint among the three groups, which may have additionally benefited glycaemic control. This explanation was observed in a study which showed that the relationship between high basal insulin doses and glycaemic control was nonlinear, with increasing insulin doses leading to smaller FBG and HbA1c reductions for doses &gt; 0.3 U/kg/day and a plateauing effect at 0.5 U/kg/day.</text><annotation id="7825"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="21050" length="7" /><text>insulin</text></annotation><annotation id="7826"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="21237" length="7" /><text>insulin</text></annotation><annotation id="7827"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="21373" length="7" /><text>insulin</text></annotation><annotation id="7828"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="21590" length="7" /><text>insulin</text></annotation><annotation id="7829"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="21657" length="7" /><text>insulin</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21787</offset><text>Moreover, hypoglycaemia and weight gain were closely associated with insulin therapy in T2D patients, in which the lower FBG target may lead to an insulin dose increase in T2D patients, which was a risk factor for hypoglycaemia and weight gain. However, another study indicated that treatment to target an FBG &lt; 5.3 mmol/L with insulin glargine was not associated with significantly increased risk for hypoglycaemia as compared to a target of FBG &lt; 6.1 mmol/L. We also found that patients among the three groups with insulin glargine therapy lasting for 24 weeks had similar hypoglycaemia incidences. Additionally, our data demonstrated that all recruited patients receiving insulin glargine had similar weight gain at the endpoint. Thus, insulin glargine therapy is a safe and effective treatment for T2D patients, even with strict FBG targets.</text><annotation id="7830"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="21934" length="7" /><text>insulin</text></annotation><annotation id="7831"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="22526" length="7" /><text>insulin</text></annotation><annotation id="7832"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="22462" length="7" /><text>insulin</text></annotation><annotation id="7833"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="22304" length="7" /><text>insulin</text></annotation><annotation id="7834"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="22115" length="7" /><text>insulin</text></annotation><annotation id="7835"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="21856" length="7" /><text>insulin</text></annotation><annotation id="7838"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="21963" length="8" /><text>patients</text></annotation><annotation id="7840"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22593" length="8" /><text>patients</text></annotation><annotation id="7841"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="22589" length="3" /><text>T2D</text></annotation><annotation id="7843"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="22230" length="3" /><text>FBG</text></annotation><annotation id="7844"><infon key="identifier">MESH:D015430</infon><infon key="type">Disease</infon><location offset="21815" length="11" /><text>weight gain</text></annotation><annotation id="7845"><infon key="type">Disease</infon><location offset="22362" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7846"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="21875" length="3" /><text>T2D</text></annotation><annotation id="7847"><infon key="type">Disease</infon><location offset="22001" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7848"><infon key="type">Disease</infon><location offset="21797" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7849"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="21908" length="3" /><text>FBG</text></annotation><annotation id="7850"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="21959" length="3" /><text>T2D</text></annotation><annotation id="7851"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22267" length="8" /><text>patients</text></annotation><annotation id="7852"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="22620" length="3" /><text>FBG</text></annotation><annotation id="7853"><infon key="identifier">MESH:D015430</infon><infon key="type">Disease</infon><location offset="22491" length="11" /><text>weight gain</text></annotation><annotation id="7854"><infon key="identifier">MESH:D015430</infon><infon key="type">Disease</infon><location offset="22019" length="11" /><text>weight gain</text></annotation><annotation id="7855"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="21879" length="8" /><text>patients</text></annotation><annotation id="7856"><infon key="type">Disease</infon><location offset="22189" length="13" /><text>hypoglycaemia</text></annotation><annotation id="7858"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22443" length="8" /><text>patients</text></annotation><annotation id="7859"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="22093" length="3" /><text>FBG</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>22637</offset><text>5. Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>22652</offset><text>In conclusion, an FBG level of 6.1 mmol/L as the insulin titration goal provided significant improvement in GV and HbA1c values in T2D patients. Therefore, an FBG of 6.1 mmol/L may possibly be a viable threshold for insulin glargine titration targeting in T2D patients.</text><annotation id="7860"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="22701" length="7" /><text>insulin</text></annotation><annotation id="7861"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="22868" length="7" /><text>insulin</text></annotation><annotation id="7862"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22912" length="8" /><text>patients</text></annotation><annotation id="7863"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="22908" length="3" /><text>T2D</text></annotation><annotation id="7864"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="22811" length="3" /><text>FBG</text></annotation><annotation id="7865"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22787" length="8" /><text>patients</text></annotation><annotation id="7866"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="22670" length="3" /><text>FBG</text></annotation><annotation id="7867"><infon key="identifier">MESH:D003924</infon><infon key="type">Disease</infon><location offset="22783" length="3" /><text>T2D</text></annotation></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>22926</offset><text>Data Availability</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>22944</offset><text>The data sets generated during and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>23114</offset><text>Conflicts of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>23136</offset><text>All authors declare that there is no conflict of interest.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>23195</offset><text>Authors' Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>23218</offset><text>JH. M. and JD. W. contributed to the conception and design of the study. L. Y., R. S., G. G., L. D., and YJ. T. contributed to the conduct/data collection. Y. Z., Q. Z., and L. Y. contributed to data analysis. L. Y. and FF. L. contributed to manuscript writing. JH. M. and JD. W. contributed to the final approval of the manuscript. Lu Yuan, Fengfei Li, Yue Zhou, Rui Sun, and Gu Gao contributed equally to this article.</text><annotation id="7868"><infon key="identifier">MESH:C537247</infon><infon key="type">Disease</infon><location offset="23480" length="2" /><text>JH</text></annotation><annotation id="7869"><infon key="identifier">MESH:C537247</infon><infon key="type">Disease</infon><location offset="23218" length="2" /><text>JH</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-85043509509</infon><infon key="name_2">surname:Karuranga;given-names:S.</infon><infon key="name_1">surname:Shaw;given-names:J. E.</infon><infon key="name_0">surname:Cho;given-names:N. H.</infon><infon key="fpage">271</infon><infon key="pub-id_doi">10.1016/j.diabres.2018.02.023</infon><infon key="pub-id_pmid">29496507</infon><infon key="year">2018</infon><infon key="source">Diabetes Research and Clinical Practice</infon><infon key="type">ref</infon><infon key="volume">138</infon><infon key="section_type">REF</infon><infon key="lpage">281</infon><offset>23639</offset><text>IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045</text></passage><passage><infon key="name_3">surname:Matthews;given-names:D. R.</infon><infon key="pub-id_other">2-s2.0-53749096863</infon><infon key="name_2">surname:Bethel;given-names:M. A.</infon><infon key="name_1">surname:Paul;given-names:S. K.</infon><infon key="name_0">surname:Holman;given-names:R. R.</infon><infon key="fpage">1577</infon><infon key="issue">15</infon><infon key="pub-id_doi">10.1056/NEJMoa0806470</infon><infon key="pub-id_pmid">18784090</infon><infon key="year">2008</infon><infon key="source">The New England Journal of Medicine</infon><infon key="type">ref</infon><infon key="volume">359</infon><infon key="section_type">REF</infon><infon key="lpage">1589</infon><infon key="name_4">surname:Neil;given-names:H. A. W.</infon><offset>23733</offset><text>10-year follow-up of intensive glucose control in type 2 diabetes</text></passage><passage><infon key="pub-id_other">2-s2.0-85070548351</infon><infon key="name_2">surname:Liu;given-names:S.</infon><infon key="name_1">surname:Huang;given-names:J.</infon><infon key="name_0">surname:Dong;given-names:Q.</infon><infon key="fpage">1303</infon><infon key="pub-id_doi">10.2147/PPA.S198908</infon><infon key="pub-id_pmid">31534317</infon><infon key="year">2019</infon><infon key="source">Patient Preference and Adherence</infon><infon key="type">ref</infon><infon key="volume">Volume 13</infon><infon key="section_type">REF</infon><infon key="lpage">1310</infon><offset>23799</offset><text>A survey on glycemic control rate of type 2 diabetes mellitus with different therapies and patients' satisfaction in China</text></passage><passage><infon key="pub-id_other">2-s2.0-0034628425</infon><infon key="volume">342</infon><infon key="section_type">REF</infon><infon key="fpage">381</infon><infon key="issue">6</infon><infon key="pub-id_doi">10.1056/nejm200002103420603</infon><infon key="year">2000</infon><infon key="source">New England Journal of Medicine</infon><infon key="type">ref</infon><infon key="lpage">389</infon><offset>23922</offset><text>Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group</text></passage><passage><infon key="volume">352</infon><infon key="section_type">REF</infon><infon key="fpage">837</infon><infon key="issue">9131</infon><infon key="year">1998</infon><infon key="source">The Lancet</infon><infon key="type">ref</infon><infon key="lpage">853</infon><offset>24147</offset><text>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group</text><annotation id="7870"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="24202" length="7" /><text>insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-0027370108</infon><infon key="volume">329</infon><infon key="section_type">REF</infon><infon key="fpage">977</infon><infon key="issue">14</infon><infon key="pub-id_doi">10.1056/nejm199309303291401</infon><infon key="year">1993</infon><infon key="source">New England Journal of Medicine</infon><infon key="type">ref</infon><infon key="lpage">986</infon><offset>24362</offset><text>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group</text><annotation id="7871"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="24473" length="7" /><text>insulin</text></annotation></passage><passage><infon key="name_2">surname:Neil;given-names:H. A.</infon><infon key="name_1">surname:Adler;given-names:A. I.</infon><infon key="name_0">surname:Stratton;given-names:I. M.</infon><infon key="fpage">405</infon><infon key="issue">7258</infon><infon key="pub-id_doi">10.1136/bmj.321.7258.405</infon><infon key="pub-id_pmid">10938048</infon><infon key="year">2000</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">321</infon><infon key="section_type">REF</infon><infon key="lpage">412</infon><offset>24570</offset><text>Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</text></passage><passage><infon key="pub-id_other">2-s2.0-0036733143</infon><infon key="volume">26</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Del Prato;given-names:S.</infon><infon key="fpage">S9</infon><infon key="issue">Supplement 3</infon><infon key="pub-id_doi">10.1038/sj.ijo.0802172</infon><infon key="pub-id_pmid">12174318</infon><infon key="year">2002</infon><infon key="source">International Journal of Obesity</infon><infon key="type">ref</infon><infon key="lpage">S17</infon><offset>24709</offset><text>In search of normoglycaemia in diabetes: controlling postprandial glucose</text></passage><passage><infon key="pub-id_other">2-s2.0-48149095259</infon><infon key="name_2">surname:Borg;given-names:R.</infon><infon key="name_1">surname:Kuenen;given-names:J.</infon><infon key="name_0">surname:Nathan;given-names:D. M.</infon><infon key="fpage">1473</infon><infon key="issue">8</infon><infon key="pub-id_doi">10.2337/dc08-0545</infon><infon key="pub-id_pmid">18540046</infon><infon key="year">2008</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="section_type">REF</infon><infon key="lpage">1478</infon><offset>24783</offset><text>Translating the A1C assay into estimated average glucose values</text><annotation id="7872"><infon key="identifier">tmVar:c|SUB|A|1|C;HGVS:c.1A&gt;C;VariantGroup:0;CorrespondingGene:3630;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="24799" length="3" /><text>A1C</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-84893503168</infon><infon key="name_2">surname:Li;given-names:H.</infon><infon key="name_1">surname:Mo;given-names:Y.</infon><infon key="name_0">surname:Zhou;given-names:J.</infon><infon key="fpage">p. e83827</infon><infon key="issue">12</infon><infon key="pub-id_doi">10.1371/journal.pone.0083827</infon><infon key="pub-id_pmid">24376762</infon><infon key="year">2013</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="section_type">REF</infon><offset>24847</offset><text>Relationship between HbA1c and continuous glucose monitoring in Chinese population: a multicenter study</text></passage><passage><infon key="pub-id_other">2-s2.0-85043492349</infon><infon key="name_2">surname:Kim;given-names:K.</infon><infon key="name_1">surname:Min;given-names:H. S.</infon><infon key="name_0">surname:Cha;given-names:J. J.</infon><infon key="fpage">367</infon><infon key="issue">2</infon><infon key="pub-id_doi">10.3904/kjim.2016.114</infon><infon key="pub-id_pmid">27809453</infon><infon key="year">2018</infon><infon key="source">The Korean Journal of Internal Medicine</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="section_type">REF</infon><infon key="lpage">382</infon><offset>24951</offset><text>Long-term study of the association of adipokines and glucose variability with diabetic complications</text></passage><passage><infon key="volume">771</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Johnson;given-names:E. L.</infon><infon key="fpage">139</infon><infon key="pub-id_doi">10.1007/978-1-4614-5441-0_13</infon><infon key="pub-id_pmid">23393677</infon><infon key="year">2012</infon><infon key="source">Advances in Experimental Medicine and Biology</infon><infon key="type">ref</infon><infon key="lpage">154</infon><offset>25052</offset><text>Glycemic variability in type 2 diabetes mellitus: oxidative stress and macrovascular complications</text></passage><passage><infon key="volume">62</infon><infon key="name_2">surname:Soupal;given-names:J.</infon><infon key="name_1">surname:Skrha;given-names:J.</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Prazny;given-names:M.</infon><infon key="fpage">S85</infon><infon key="issue">11 Supplement 4</infon><infon key="pub-id_pmid">27921431</infon><infon key="year">2016</infon><infon key="source">Vnitrni Lekarstvi</infon><infon key="type">ref</infon><infon key="lpage">s93</infon><offset>25151</offset><text>Short-term and long-term glycemic variability and its relationship to microvascular complications of diabetes</text></passage><passage><infon key="pub-id_other">2-s2.0-85036620716</infon><infon key="name_2">surname:Battelino;given-names:T.</infon><infon key="name_1">surname:Nimri;given-names:R.</infon><infon key="name_0">surname:Danne;given-names:T.</infon><infon key="fpage">1631</infon><infon key="issue">12</infon><infon key="pub-id_doi">10.2337/dc17-1600</infon><infon key="pub-id_pmid">29162583</infon><infon key="year">2017</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="section_type">REF</infon><infon key="lpage">1640</infon><offset>25261</offset><text>International consensus on use of continuous glucose monitoring</text></passage><passage><infon key="name_3">surname:Holl;given-names:R. W.</infon><infon key="pub-id_other">2-s2.0-85032001208</infon><infon key="name_2">surname:Bergenstal;given-names:R. M.</infon><infon key="name_1">surname:Peters;given-names:A. L.</infon><infon key="name_0">surname:Petrie;given-names:J. R.</infon><infon key="fpage">2319</infon><infon key="issue">12</infon><infon key="pub-id_doi">10.1007/s00125-017-4463-4</infon><infon key="pub-id_pmid">29067486</infon><infon key="year">2017</infon><infon key="source">Diabetologia</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="section_type">REF</infon><infon key="lpage">2328</infon><infon key="name_5">surname:Heinemann;given-names:L.</infon><infon key="name_4">surname:Fleming;given-names:G. A.</infon><offset>25325</offset><text>Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group</text></passage><passage><infon key="pub-id_other">2-s2.0-85066997802</infon><infon key="name_2">surname:Bergenstal;given-names:R. M.</infon><infon key="name_1">surname:Danne;given-names:T.</infon><infon key="name_0">surname:Battelino;given-names:T.</infon><infon key="fpage">1593</infon><infon key="issue">8</infon><infon key="pub-id_doi">10.2337/dci19-0028</infon><infon key="pub-id_pmid">31177185</infon><infon key="year">2019</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="section_type">REF</infon><infon key="lpage">1603</infon><offset>25554</offset><text>Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range</text></passage><passage><infon key="pub-id_other">2-s2.0-34648813263</infon><infon key="name_1">surname:Kennedy;given-names:L.</infon><infon key="name_0">surname:Lansang;given-names:C. M.</infon><infon key="fpage">573</infon><infon key="issue">5</infon><infon key="pub-id_doi">10.1586/17446651.2.5.573</infon><infon key="pub-id_pmid">30736120</infon><infon key="year">2007</infon><infon key="source">Expert Review of Endocrinology and Metabolism</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="section_type">REF</infon><infon key="lpage">585</infon><offset>25692</offset><text>Insulin glargine: a basal insulin for the management of diabetes</text><annotation id="7873"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="25718" length="7" /><text>insulin</text></annotation><annotation id="7874"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="25692" length="7" /><text>Insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-84919999219</infon><infon key="name_2">surname:Buse;given-names:J. B.</infon><infon key="name_1">surname:Bergenstal;given-names:R. M.</infon><infon key="name_0">surname:Inzucchi;given-names:S. E.</infon><infon key="fpage">140</infon><infon key="issue">1</infon><infon key="pub-id_doi">10.2337/dc14-2441</infon><infon key="pub-id_pmid">25538310</infon><infon key="year">2015</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="section_type">REF</infon><infon key="lpage">149</infon><offset>25757</offset><text>Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</text></passage><passage><infon key="pub-id_other">2-s2.0-85070223271</infon><infon key="name_2">surname:Pfohl;given-names:M.</infon><infon key="name_1">surname:Anderten;given-names:H.</infon><infon key="name_0">surname:Fritsche;given-names:A.</infon><infon key="fpage">p. e000668</infon><infon key="issue">1</infon><infon key="pub-id_doi">10.1136/bmjdrc-2019-000668</infon><infon key="pub-id_pmid">31423316</infon><infon key="year">2019</infon><infon key="source">BMJ Open Diabetes Research &amp; Care</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="section_type">REF</infon><offset>25963</offset><text>HbA1c target achievement in the elderly: results of the titration and optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs</text><annotation id="7875"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="26070" length="7" /><text>insulin</text></annotation></passage><passage><infon key="name_3">surname:Kaneto;given-names:H.</infon><infon key="name_2">surname:Sanefuji;given-names:H.</infon><infon key="name_1">surname:Okamura;given-names:N.</infon><infon key="name_0">surname:Nakashima;given-names:K.</infon><infon key="fpage">p. 1552</infon><infon key="issue">1</infon><infon key="pub-id_doi">10.1038/s41598-020-58574-7</infon><infon key="pub-id_pmid">32005949</infon><infon key="year">2020</infon><infon key="source">Scientific Reports</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="section_type">REF</infon><offset>26174</offset><text>Practical application of short-term intensive insulin therapy based on the concept of "treat to target" to reduce hypoglycaemia in routine clinical site</text><annotation id="7876"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="26220" length="7" /><text>insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-85066484384</infon><infon key="name_2">surname:Zhu;given-names:D.</infon><infon key="name_1">surname:Weng;given-names:J.</infon><infon key="name_0">surname:Jia;given-names:W.</infon><infon key="fpage">p. e3158</infon><infon key="issue">6</infon><infon key="pub-id_doi">10.1002/dmrr.3158</infon><infon key="pub-id_pmid">30908791</infon><infon key="year">2019</infon><infon key="source">Diabetes Metab Res Rev</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="section_type">REF</infon><offset>26327</offset><text>Standards of medical care for type 2 diabetes in China 2019</text></passage><passage><infon key="pub-id_other">2-s2.0-85039728203</infon><infon key="volume">41</infon><infon key="section_type">REF</infon><infon key="fpage">S55</infon><infon key="issue">Supplement 1</infon><infon key="pub-id_doi">10.2337/dc18-S006</infon><infon key="pub-id_pmid">29222377</infon><infon key="year">2018</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="lpage">S64</infon><offset>26387</offset><text>6. Glycemic Targets:Standards of medical care in diabetes-2018</text></passage><passage><infon key="pub-id_other">2-s2.0-84948695792</infon><infon key="pub-id_publisher-id">903524</infon><infon key="volume">2015</infon><infon key="name_2">surname:Fu;given-names:L.-y.</infon><infon key="name_1">surname:Xu;given-names:X.-h.</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Li;given-names:F.-f.</infon><infon key="fpage">5</infon><infon key="pub-id_doi">10.1155/2015/903524</infon><infon key="year">2015</infon><infon key="source">International Journal of Endocrinology</infon><infon key="type">ref</infon><offset>26450</offset><text>Influence of acarbose on plasma glucose fluctuations in insulin-treated patients with type 2 diabetes: a pilot study</text><annotation id="7877"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="26506" length="7" /><text>insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-84957090643</infon><infon key="volume">2016, article 1028945</infon><infon key="name_2">surname:Zhang;given-names:W. L.</infon><infon key="name_1">surname:Fu;given-names:L. Y.</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Li;given-names:F. F.</infon><infon key="fpage">1</infon><infon key="pub-id_doi">10.1155/2016/1028945</infon><infon key="year">2016</infon><infon key="source">Journal Diabetes Research</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>26567</offset><text>Blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections</text></passage><passage><infon key="pub-id_other">2-s2.0-85057011337</infon><infon key="name_2">surname:Jing;given-names:T.</infon><infon key="name_1">surname:Li;given-names:F.</infon><infon key="name_0">surname:Yuan;given-names:L.</infon><infon key="fpage">2347</infon><infon key="issue">6</infon><infon key="pub-id_doi">10.1007/s13300-018-0522-1</infon><infon key="pub-id_pmid">30341664</infon><infon key="year">2018</infon><infon key="source">Diabetes Ther</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="lpage">2356</infon><offset>26661</offset><text>Insulin injection technique is associated with glycemic variability in patients with type 2 diabetes</text><annotation id="7878"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="26661" length="7" /><text>Insulin</text></annotation></passage><passage><infon key="volume">2020, article 8152640</infon><infon key="name_2">surname:Ren;given-names:Y.-f.</infon><infon key="name_1">surname:Liu;given-names:X.-m.</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Liu;given-names:B.-l.</infon><infon key="pub-id_doi">10.1155/2020/8152640</infon><infon key="year">2020</infon><infon key="source">Journal Diabetes Research</infon><infon key="type">ref</infon><offset>26762</offset><text>Sexual differences in response to mid- or low-premixed insulin analogue in patients with type 2 diabetes</text><annotation id="7879"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="26817" length="7" /><text>insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-85067398731</infon><infon key="name_2">surname:Yuan;given-names:G.</infon><infon key="name_1">surname:Ma;given-names:J.</infon><infon key="name_0">surname:Yang;given-names:W.</infon><infon key="fpage">1973</infon><infon key="issue">8</infon><infon key="pub-id_doi">10.1111/dom.13733</infon><infon key="pub-id_pmid">30938035</infon><infon key="year">2019</infon><infon key="source">Diabetes, Obesity &amp; Metabolism</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="section_type">REF</infon><infon key="lpage">1977</infon><offset>26867</offset><text>Determining the optimal fasting glucose target for patients with type 2 diabetes: results of the multicentre, open-label, randomized-controlled FPG GOAL trial</text></passage><passage><infon key="volume">39</infon><infon key="section_type">REF</infon><infon key="fpage">1089</infon><infon key="issue">7</infon><infon key="pub-id_pmid">27289122</infon><infon key="year">2016</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="lpage">1100</infon><offset>27026</offset><text>Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study</text></passage><passage><infon key="name_3">surname:Hosseinpanah;given-names:F.</infon><infon key="pub-id_other">2-s2.0-85065192206</infon><infon key="name_2">surname:Malek;given-names:M.</infon><infon key="name_1">surname:Khamseh;given-names:M. E.</infon><infon key="name_0">surname:Chehregosha;given-names:H.</infon><infon key="fpage">853</infon><infon key="issue">3</infon><infon key="pub-id_doi">10.1007/s13300-019-0619-1</infon><infon key="pub-id_pmid">31037553</infon><infon key="year">2019</infon><infon key="source">Diabetes Ther</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="section_type">REF</infon><infon key="lpage">863</infon><infon key="name_4">surname:Ismail-Beigi;given-names:F.</infon><offset>27191</offset><text>A view beyond HbA1c: role of continuous glucose monitoring</text></passage><passage><infon key="pub-id_other">2-s2.0-33645745733</infon><infon key="name_2">surname:Ginet;given-names:C.</infon><infon key="name_1">surname:Mas;given-names:E.</infon><infon key="name_0">surname:Monnier;given-names:L.</infon><infon key="fpage">1681</infon><infon key="issue">14</infon><infon key="pub-id_doi">10.1001/jama.295.14.1681</infon><infon key="pub-id_pmid">16609090</infon><infon key="year">2006</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">295</infon><infon key="section_type">REF</infon><infon key="lpage">1687</infon><offset>27250</offset><text>Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes</text></passage><passage><infon key="pub-id_other">2-s2.0-85051719673</infon><infon key="name_2">surname:Kirigaya;given-names:J.</infon><infon key="name_1">surname:Iwahashi;given-names:N.</infon><infon key="name_0">surname:Takahashi;given-names:H.</infon><infon key="fpage">p. 116</infon><infon key="issue">1</infon><infon key="pub-id_doi">10.1186/s12933-018-0761-5</infon><infon key="pub-id_pmid">30121076</infon><infon key="year">2018</infon><infon key="source">Cardiovascular Diabetology</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="section_type">REF</infon><offset>27390</offset><text>Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome</text></passage><passage><infon key="pub-id_other">2-s2.0-85056161096</infon><infon key="name_2">surname:Zhang;given-names:L.</infon><infon key="name_1">surname:Ma;given-names:X.</infon><infon key="name_0">surname:Lu;given-names:J.</infon><infon key="fpage">753</infon><infon key="issue">3</infon><infon key="pub-id_doi">10.1111/jdi.12957</infon><infon key="pub-id_pmid">30306722</infon><infon key="year">2019</infon><infon key="source">J Diabetes Investig</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="section_type">REF</infon><infon key="lpage">759</infon><offset>27518</offset><text>Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes</text></passage><passage><infon key="name_3">surname:Wilhelm;given-names:K.</infon><infon key="pub-id_other">2-s2.0-76249126377</infon><infon key="name_2">surname:Hoffmann;given-names:C.</infon><infon key="name_1">surname:Koehler;given-names:C.</infon><infon key="name_0">surname:Hanefeld;given-names:M.</infon><infon key="fpage">175</infon><infon key="issue">2</infon><infon key="pub-id_doi">10.1111/j.1464-5491.2009.02915.x</infon><infon key="pub-id_pmid">20546261</infon><infon key="year">2010</infon><infon key="source">Diabetic Medicine</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="section_type">REF</infon><infon key="lpage">180</infon><infon key="name_5">surname:Gerstein;given-names:H.</infon><infon key="name_4">surname:Kamke;given-names:W.</infon><offset>27681</offset><text>Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes</text><annotation id="7880"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="27742" length="7" /><text>insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-85048235748</infon><infon key="name_2">surname:Li;given-names:P.</infon><infon key="name_1">surname:Bi;given-names:Y.</infon><infon key="name_0">surname:Yin;given-names:T. T.</infon><infon key="fpage">1253</infon><infon key="issue">3</infon><infon key="pub-id_doi">10.1007/s13300-018-0412-6</infon><infon key="pub-id_pmid">29744819</infon><infon key="year">2018</infon><infon key="source">Diabetes Ther</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="lpage">1267</infon><offset>27881</offset><text>Comparison of glycemic variability in Chinese T2DM patients treated with exenatide or insulin glargine: a randomized controlled trial</text><annotation id="7881"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="27967" length="7" /><text>insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-70350639460</infon><infon key="name_2">surname:Owens;given-names:D. R.</infon><infon key="name_1">surname:Colette;given-names:C.</infon><infon key="name_0">surname:Monnier;given-names:L.</infon><infon key="fpage">393</infon><infon key="issue">5</infon><infon key="pub-id_doi">10.1002/dmrr.962</infon><infon key="pub-id_pmid">19437415</infon><infon key="year">2009</infon><infon key="source">Diabetes/Metabolism Research and Reviews</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="section_type">REF</infon><infon key="lpage">402</infon><offset>28015</offset><text>Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept</text></passage><passage><infon key="pub-id_other">2-s2.0-33646338641</infon><infon key="name_2">surname:Chalew;given-names:S. A.</infon><infon key="name_1">surname:Hempe;given-names:J. M.</infon><infon key="name_0">surname:McCarter;given-names:R. J.</infon><infon key="fpage">352</infon><infon key="issue">2</infon><infon key="pub-id_doi">10.2337/diacare.29.02.06.dc05-1594</infon><infon key="pub-id_pmid">16443886</infon><infon key="year">2006</infon><infon key="source">Diabetes Care</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="section_type">REF</infon><infon key="lpage">355</infon><offset>28144</offset><text>Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial</text></passage><passage><infon key="pub-id_other">2-s2.0-77953637843</infon><infon key="name_2">surname:Krishnarajah;given-names:G.</infon><infon key="name_1">surname:Hernandez-Medina;given-names:M.</infon><infon key="name_0">surname:Nalysnyk;given-names:L.</infon><infon key="fpage">288</infon><infon key="issue">4</infon><infon key="pub-id_doi">10.1111/j.1463-1326.2009.01160.x</infon><infon key="year">2010</infon><infon key="source">Diabetes, Obesity &amp; Metabolism</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="section_type">REF</infon><infon key="lpage">298</infon><offset>28323</offset><text>Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature</text></passage><passage><infon key="pub-id_other">2-s2.0-79951941643</infon><infon key="name_2">surname:Tao;given-names:H.</infon><infon key="name_1">surname:Mi;given-names:S.</infon><infon key="name_0">surname:Su;given-names:G.</infon><infon key="fpage">p. 19</infon><infon key="issue">1</infon><infon key="pub-id_doi">10.1186/1475-2840-10-19</infon><infon key="pub-id_pmid">21349201</infon><infon key="year">2011</infon><infon key="source">Cardiovascular Diabetology</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="section_type">REF</infon><offset>28451</offset><text>Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes</text></passage><passage><infon key="name_3">surname:Wu;given-names:J.</infon><infon key="pub-id_other">2-s2.0-84880884226</infon><infon key="name_2">surname:Jiao;given-names:X.</infon><infon key="name_1">surname:Xu;given-names:X.</infon><infon key="name_0">surname:Zhang;given-names:X.</infon><infon key="fpage">1</infon><infon key="pub-id_doi">10.1155/2013/576916</infon><infon key="year">2013</infon><infon key="source">Journal Diabetes Research</infon><infon key="type">ref</infon><infon key="volume">2013, article 576916</infon><infon key="section_type">REF</infon><infon key="lpage">6</infon><infon key="name_5">surname:Lv;given-names:X.</infon><infon key="name_4">surname:Zhou;given-names:S.</infon><offset>28577</offset><text>The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus</text></passage><passage><infon key="pub-id_other">2-s2.0-78651348331</infon><infon key="name_2">surname:Ran;given-names:X.</infon><infon key="name_1">surname:Li;given-names:H.</infon><infon key="name_0">surname:Zhou;given-names:J.</infon><infon key="fpage">CR9</infon><infon key="issue">1</infon><infon key="pub-id_doi">10.12659/msm.881318</infon><infon key="pub-id_pmid">21169911</infon><infon key="year">2011</infon><infon key="source">Medical Science Monitor</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="section_type">REF</infon><infon key="lpage">CR13</infon><offset>28683</offset><text>Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring</text></passage><passage><infon key="name_3">surname:Traylor;given-names:L.</infon><infon key="pub-id_other">2-s2.0-85063598624</infon><infon key="name_2">surname:Dex;given-names:T.</infon><infon key="name_1">surname:Skolnik;given-names:N.</infon><infon key="name_0">surname:Umpierrez;given-names:G. E.</infon><infon key="fpage">1305</infon><infon key="issue">6</infon><infon key="pub-id_doi">10.1111/dom.13653</infon><infon key="pub-id_pmid">30724009</infon><infon key="year">2019</infon><infon key="source">Diabetes, Obesity &amp; Metabolism</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="section_type">REF</infon><infon key="lpage">1310</infon><infon key="name_5">surname:Shaefer;given-names:C.</infon><infon key="name_4">surname:Chao;given-names:J.</infon><offset>28805</offset><text>When basal insulin is not enough: a dose-response relationship between insulin glargine 100 units/mL and glycaemic control</text><annotation id="7882"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="28876" length="7" /><text>insulin</text></annotation><annotation id="7883"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="28816" length="7" /><text>insulin</text></annotation></passage><passage><infon key="pub-id_other">2-s2.0-35048841093</infon><infon key="volume">9</infon><infon key="name_1">surname:Khan;given-names:R.</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Russell-Jones;given-names:D.</infon><infon key="fpage">799</infon><infon key="issue">6</infon><infon key="pub-id_doi">10.1111/j.1463-1326.2006.00686.x</infon><infon key="year">2007</infon><infon key="source">Diabetes, Obesity &amp; Metabolism</infon><infon key="type">ref</infon><infon key="lpage">812</infon><offset>28928</offset><text>Insulin-associated weight gain in diabetes--causes, effects and coping strategies</text><annotation id="7884"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="28928" length="7" /><text>Insulin</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">JDR2021-5524313.001.jpg</infon><infon key="id">fig1</infon><infon key="type">fig_caption</infon><offset>29010</offset><text>Study flow chart.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">JDR2021-5524313.002.jpg</infon><infon key="id">fig2</infon><infon key="type">fig_caption</infon><offset>29028</offset><text>A total of 71 patients finished the study.</text><annotation id="7885"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="29042" length="8" /><text>patients</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">JDR2021-5524313.003.jpg</infon><infon key="id">fig3</infon><infon key="type">fig_caption</infon><offset>29071</offset><text>The insulin dose among the three groups during the study period.</text><annotation id="7886"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="29075" length="7" /><text>insulin</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab1.xml</infon><infon key="id">tab1</infon><infon key="type">table_caption</infon><offset>29136</offset><text>Titration regimes for recruited subjects.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab1.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;FBG (mmol/L)&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;Insulin dose&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;All groups &amp;lt; 3.9 or nocturnal hypoglycaemia&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-2 U&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center" colspan="2" rowspan="1"&gt; &lt;hr/&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 2: 3.9 &amp;lt; FBG &lt;= 5.6&lt;/td&gt;&lt;td align="center" rowspan="2" colspan="1"&gt;According to clinical condition by the investigator&lt;break/&gt;-1-2 U or no change&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 3: 3.9 &amp;lt; FBG &lt;= 6.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center" colspan="2" rowspan="1"&gt; &lt;hr/&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 1: 3.9 &amp;lt; FBG &lt;= 5.6&lt;/td&gt;&lt;td align="center" rowspan="3" colspan="1"&gt;No change&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 2: 5.6 &amp;lt; FBG &lt;= 6.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 3: 6.1 &amp;lt; FBG &lt;= 7.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center" colspan="2" rowspan="1"&gt; &lt;hr/&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 1: 5.6 &amp;lt; FBG &amp;lt; 10.0&lt;/td&gt;&lt;td align="center" rowspan="3" colspan="1"&gt;+2 U&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 2: 6.1 &amp;lt; FBG &amp;lt; 10.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Group 3: 7.0 &amp;lt; FBG &amp;lt; 10.0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center" colspan="2" rowspan="1"&gt; &lt;hr/&gt; &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;All groups &amp;gt; 10.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;According to clinical condition by the investigator&lt;break/&gt;+2-4 U&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">tab1</infon><infon key="type">table</infon><offset>29178</offset><text>FBG (mmol/L) Insulin dose   All groups &lt; 3.9 or nocturnal hypoglycaemia -2 U      Group 2: 3.9 &lt; FBG &lt;= 5.6 According to clinical condition by the investigator-1-2 U or no change   Group 3: 3.9 &lt; FBG &lt;= 6.1      Group 1: 3.9 &lt; FBG &lt;= 5.6 No change   Group 2: 5.6 &lt; FBG &lt;= 6.1   Group 3: 6.1 &lt; FBG &lt;= 7.0      Group 1: 5.6 &lt; FBG &lt; 10.0 +2 U   Group 2: 6.1 &lt; FBG &lt; 10.0   Group 3: 7.0 &lt; FBG &lt; 10.0      All groups &gt; 10.0 According to clinical condition by the investigator+2-4 U   </text><annotation id="7888"><infon key="identifier">3630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">173</infon><location offset="29191" length="7" /><text>Insulin</text></annotation><annotation id="7889"><infon key="type">Disease</infon><location offset="29236" length="13" /><text>hypoglycaemia</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab1.xml</infon><infon key="id">tab1</infon><infon key="type">table_footnote</infon><offset>29671</offset><text>FBG: fasting blood glucose.</text><annotation id="7891"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="29690" length="7" /><text>glucose</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab2.xml</infon><infon key="id">tab2</infon><infon key="type">table_caption</infon><offset>29699</offset><text>The baseline characteristics of subjects among the three groups.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab2.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Group&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;1&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;2&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;3&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt; &lt;italic&gt;p&lt;/italic&gt; value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Gender (M/F)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5/5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;14/12&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;26/9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.16&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Age (year)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;56.5 +- 8.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;57.9 +- 4.7&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;53.8 +- 7.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.06&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Duration (month)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;103.1 +- 66.4&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;113.6 +- 62.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;107.9 +- 65.1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.89&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" colspan="4" rowspan="1"&gt;Numbers of OADs (&lt;italic&gt;n&lt;/italic&gt;)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.06&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; 1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; 2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;12&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;24&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; 3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;9&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;OADs&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Met(-/+)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;4/6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;7/19&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;4/31&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.10&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; SU (-/+)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2/8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;9/17&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5/30&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Weight (kg)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;68.8 +- 10.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;65.2 +- 12.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;70.9 +- 9.5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;25.7 +- 3.1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;24.6 +- 3.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;25.6 +- 2.4&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.29&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Waist (cm)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;92.2 +- 10.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;89.9 +- 9.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;93.0 +- 7.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.41&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Hb (g)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;139.4 +- 10.5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;143.6 +- 10.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;144.0 +- 11.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.48&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;Cr (mmol/L)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;62.5 +- 13.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;59.0 +- 14.7&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;65.0 +- 12.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.26&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;ALT (U/L)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;31.1 +- 15.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;29.3 +- 14.5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;35.6 +- 18.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.34&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;AST (U/L)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;20.0 +- 6.5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;20.8 +- 7.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;21.3 +- 10.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.91&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;TG (mmol/L)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.1 +- 1.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.0 +- 1.4&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.0 +- 1.1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.94&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;TC (mmol/L)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5.2 +- 1.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5.5 +- 1.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5.2 +- 1.1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.59&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;HDL (mmol/L)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.3 +- 0.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.5 +- 0.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.3 +- 0.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.09&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;LDL (mmol/L)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.8 +- 0.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.9 +- 0.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.8 +- 0.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.98&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">tab2</infon><infon key="type">table</infon><offset>29764</offset><text>Group 1 2 3 p value   Gender (M/F) 5/5 14/12 26/9 0.16   Age (year) 56.5 +- 8.9 57.9 +- 4.7 53.8 +- 7.3 0.06   Duration (month) 103.1 +- 66.4 113.6 +- 62.8 107.9 +- 65.1 0.89   Numbers of OADs (n) 0.06    1 1 8 2     2 8 12 24     3 1 6 9    OADs        Met(-/+) 4/6 7/19 4/31 0.10    SU (-/+) 2/8 9/17 5/30 0.17   Weight (kg) 68.8 +- 10.2 65.2 +- 12.6 70.9 +- 9.5 0.13   BMI (kg/m2) 25.7 +- 3.1 24.6 +- 3.0 25.6 +- 2.4 0.29   Waist (cm) 92.2 +- 10.6 89.9 +- 9.8 93.0 +- 7.6 0.41   Hb (g) 139.4 +- 10.5 143.6 +- 10.0 144.0 +- 11.3 0.48   Cr (mmol/L) 62.5 +- 13.0 59.0 +- 14.7 65.0 +- 12.2 0.26   ALT (U/L) 31.1 +- 15.9 29.3 +- 14.5 35.6 +- 18.3 0.34   AST (U/L) 20.0 +- 6.5 20.8 +- 7.2 21.3 +- 10.2 0.91   TG (mmol/L) 2.1 +- 1.6 2.0 +- 1.4 2.0 +- 1.1 0.94   TC (mmol/L) 5.2 +- 1.0 5.5 +- 1.2 5.2 +- 1.1 0.59   HDL (mmol/L) 1.3 +- 0.3 1.5 +- 0.3 1.3 +- 0.3 0.09   LDL (mmol/L) 2.8 +- 0.6 2.9 +- 0.9 2.8 +- 0.9 0.98   </text><annotation id="7892"><infon key="identifier">26503</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56571</infon><location offset="30416" length="3" /><text>AST</text></annotation><annotation id="7893"><infon key="identifier">MESH:D000092582</infon><infon key="type">Disease</infon><location offset="30006" length="4" /><text>OADs</text></annotation><annotation id="7894"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30049" length="2" /><text>SU</text></annotation><annotation id="7895"><infon key="identifier">MESH:D000092582</infon><infon key="type">Disease</infon><location offset="29952" length="4" /><text>OADs</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab2.xml</infon><infon key="id">tab2</infon><infon key="type">table_footnote</infon><offset>30691</offset><text>BMI: body mass index; Hb: hemoglobin; Cr: creatinine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; TG: triglyceride; TC: total cholesterol; OADs: oral antidiabetic drugs; Met: metformin; SU: sulfonylurea.</text><annotation id="7896"><infon key="identifier">2875</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">134231</infon><location offset="30750" length="24" /><text>alanine aminotransferase</text></annotation><annotation id="7897"><infon key="identifier">26503</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">56571</infon><location offset="30776" length="3" /><text>AST</text></annotation><annotation id="7898"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30939" length="4" /><text>OADs</text></annotation><annotation id="7899"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30986" length="2" /><text>SU</text></annotation><annotation id="7900"><infon key="identifier">MESH:D002784</infon><infon key="type">Chemical</infon><location offset="30926" length="11" /><text>cholesterol</text></annotation><annotation id="7901"><infon key="identifier">MESH:D013667</infon><infon key="type">Chemical</infon><location offset="30916" length="2" /><text>TC</text></annotation><annotation id="7902"><infon key="identifier">MESH:D013866</infon><infon key="type">Chemical</infon><location offset="30898" length="2" /><text>TG</text></annotation><annotation id="7903"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30854" length="5" /><text>LDL-c</text></annotation><annotation id="7904"><infon key="identifier">MESH:D003404</infon><infon key="type">Chemical</infon><location offset="30733" length="10" /><text>creatinine</text></annotation><annotation id="7905"><infon key="identifier">MESH:D013453</infon><infon key="type">Chemical</infon><location offset="30990" length="12" /><text>sulfonylurea</text></annotation><annotation id="7906"><infon key="identifier">MESH:D008715</infon><infon key="type">Chemical</infon><location offset="30970" length="3" /><text>Met</text></annotation><annotation id="7907"><infon key="identifier">MESH:D014280</infon><infon key="type">Chemical</infon><location offset="30902" length="12" /><text>triglyceride</text></annotation><annotation id="7908"><infon key="identifier">MESH:D002857</infon><infon key="type">Chemical</infon><location offset="30729" length="2" /><text>Cr</text></annotation><annotation id="7909"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="30945" length="23" /><text>oral antidiabetic drugs</text></annotation><annotation id="7910"><infon key="identifier">MESH:D008687</infon><infon key="type">Chemical</infon><location offset="30975" length="9" /><text>metformin</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab3.xml</infon><infon key="id">tab3</infon><infon key="type">table_caption</infon><offset>31004</offset><text>The FBG among the three groups.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab3.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Group&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;V 1&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;V 18&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt; &lt;italic&gt;p&lt;/italic&gt; &lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.3 +- 0.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5.5 +- 0.5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.6 +- 1.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5.4 +- 0.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.3 +- 1.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;6.4 +- 1.1&lt;sup&gt;*&lt;/sup&gt;&lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">tab3</infon><infon key="type">table</infon><offset>31036</offset><text>Group V 1 V 18 p   1 8.3 +- 0.9 5.5 +- 0.5 0.00   2 8.6 +- 1.9 5.4 +- 0.6 0.00   3 8.3 +- 1.6 6.4 +- 1.1*# 0.00   </text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab3.xml</infon><infon key="id">tab3</infon><infon key="type">table_footnote</infon><offset>31153</offset><text>*: vs. Group 1 p &lt; 0.05; #: vs. Group 2 p &lt; 0.05; FBG: fasting blood glucose.</text><annotation id="7911"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="31222" length="7" /><text>glucose</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab4.xml</infon><infon key="id">tab4</infon><infon key="type">table_caption</infon><offset>31233</offset><text>The changes of HbA1c among the three groups.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab4.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Group&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;V 1&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;V 18&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt; &lt;italic&gt;p&lt;/italic&gt; &lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;The absolute change value&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;The percent of change value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.0 +- 0.7&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;7.2 +- 0.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.8 +- 0.3&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;9.7 +- 3.4&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.4 +- 0.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;6.8 +- 0.7&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.6 +- 0.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;18.5 +- 9.3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.5 +- 0.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;7.3 +- 0.8&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.2 +- 0.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;13.8 +- 9.2&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">tab4</infon><infon key="type">table</infon><offset>31278</offset><text>Group V 1 V 18 p The absolute change value The percent of change value   1 8.0 +- 0.7 7.2 +- 0.6 0.00 0.8 +- 0.3* 9.7 +- 3.4*   2 8.4 +- 0.8 6.8 +- 0.7 0.00 1.6 +- 0.9 18.5 +- 9.3   3 8.5 +- 0.8 7.3 +- 0.8* 0.00 1.2 +- 0.8 13.8 +- 9.2*   </text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab4.xml</infon><infon key="id">tab4</infon><infon key="type">table_footnote</infon><offset>31525</offset><text>*: vs. Group 2 p &lt; 0.05; HbA1c: glycated hemoglobin A1c (%).</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab5.xml</infon><infon key="id">tab5</infon><infon key="type">table_caption</infon><offset>31592</offset><text>The CGM profile of the three groups.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab5.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align="left" rowspan="1" colspan="1"&gt;Group&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;1&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;2&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt;3&lt;/th&gt;&lt;th align="center" rowspan="1" colspan="1"&gt; &lt;italic&gt;p&lt;/italic&gt; &lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;MG&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Baseline&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;10.1 +- 1.7&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;10.4 +- 2.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;10.0 +- 1.7&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.70&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Endpoint&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.2 +- 1.3&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;7.4 +- 1.2&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;8.9 +- 1.8&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; &lt;italic&gt;Delta&lt;/italic&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.8 +- 2.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;3.0 +- 1.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.1 +- 2.1&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;SD&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Baseline&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.8 +- 0.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.3 +- 1.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.1 +- 0.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.30&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Endpoint&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.3 +- 1.0&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.8 +- 0.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;2.6 +- 1.0&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; &lt;italic&gt;Delta&lt;/italic&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-0.5 +- 1.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.5 +- 1.4&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-0.4 +- 1.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;CV%&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Baseline&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;17.8 +- 4.5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;22.1 +- 8.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;21.7 +- 8.4&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.35&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Endpoint&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;27.7 +- 9.7&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;24.1 +- 10.5&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;28.7 +- 10.2&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.23&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; &lt;italic&gt;Delta&lt;/italic&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-10.0 +- 11.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-2.1 +- 14.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-7.0 +- 11.6&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.17&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;MAGE&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Baseline&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;4.4 +- 1.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;6.2 +- 3.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5.5 +- 2.7&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.22&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Endpoint&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;5.7 +- 3.2&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;4.7 +- 2.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;6.0 +- 2.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.26&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; &lt;italic&gt;Delta&lt;/italic&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-1.3 +- 2.9&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;1.4 +- 3.8&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;-0.5 +- 3.3&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;AUC&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Baseline&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;183.3 (60.7, 441.7)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;327.2 (115.4, 694.6)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;212.6 (64.8, 502.9)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.63&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Endpoint&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;104.1 (17.7, 204.1)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;19.7 (0, 120.0)&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;128.8 (31.1, 401.0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; &lt;italic&gt;Delta&lt;/italic&gt; &lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;102.7 (-45.7, 282.5)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;229.4 (98.6, 502.7)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;26.41 (-110.3, 349.9)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt;AOC&lt;/td&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;td rowspan="1" colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Baseline&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; Endpoint&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.44&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" rowspan="1" colspan="1"&gt; &lt;italic&gt;Delta&lt;/italic&gt; &lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0 (0, 0)&lt;/td&gt;&lt;td align="center" rowspan="1" colspan="1"&gt;0.49&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">tab5</infon><infon key="type">table</infon><offset>31629</offset><text>Group 1 2 3 p   MG        Baseline 10.1 +- 1.7 10.4 +- 2.0 10.0 +- 1.7 0.70    Endpoint 8.2 +- 1.3* 7.4 +- 1.2* 8.9 +- 1.8* 0.00    Delta 1.8 +- 2.0 3.0 +- 1.9 1.1 +- 2.1 0.00   SD        Baseline 1.8 +- 0.8 2.3 +- 1.0 2.1 +- 0.8 0.30    Endpoint 2.3 +- 1.0 1.8 +- 0.9 2.6 +- 1.0* 0.01    Delta -0.5 +- 1.2 0.5 +- 1.4 -0.4 +- 1.2 0.01   CV%        Baseline 17.8 +- 4.5 22.1 +- 8.9 21.7 +- 8.4 0.35    Endpoint 27.7 +- 9.7* 24.1 +- 10.5 28.7 +- 10.2* 0.23    Delta -10.0 +- 11.3 -2.1 +- 14.6 -7.0 +- 11.6 0.17   MAGE        Baseline 4.4 +- 1.3 6.2 +- 3.2 5.5 +- 2.7 0.22    Endpoint 5.7 +- 3.2 4.7 +- 2.8 6.0 +- 2.8 0.26    Delta -1.3 +- 2.9 1.4 +- 3.8 -0.5 +- 3.3 0.04   AUC        Baseline 183.3 (60.7, 441.7) 327.2 (115.4, 694.6) 212.6 (64.8, 502.9) 0.63    Endpoint 104.1 (17.7, 204.1) 19.7 (0, 120.0)* 128.8 (31.1, 401.0) 0.02   Delta 102.7 (-45.7, 282.5) 229.4 (98.6, 502.7) 26.41 (-110.3, 349.9) 0.01   AOC        Baseline 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.58    Endpoint 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.44   Delta 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.49   </text><annotation id="7912"><infon key="identifier">MESH:D018149</infon><infon key="type">Disease</infon><location offset="31645" length="2" /><text>MG</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">tab5.xml</infon><infon key="id">tab5</infon><infon key="type">table_footnote</infon><offset>32719</offset><text> Delta: baseline value-endpoint value; *: baseline vs. endpoint p &lt; 0.05; MG: the 24 hrs mean glucose concentration (mmol/L); SD: the 24 hrs standard deviation of the MG (mmol/L); CV%: coefficient of variation (%); MAGE: the 24 hrs mean amplitude of glycaemic excursion (mmol/L); AUC: the incremental area under the curve &gt; 10 mmol/L (mmol/L*day); AOC: the incremental area over the curve &lt; 3.9 mmol/L (mmol/L*day).</text><annotation id="7913"><infon key="identifier">MESH:D005947</infon><infon key="type">Chemical</infon><location offset="32813" length="7" /><text>glucose</text></annotation></passage><relation id="R1"><infon key="score">0.8081</infon><infon key="role1">Chemical|MESH:D005947</infon><infon key="role2">Disease|MESH:D003924</infon><infon key="type">Association</infon></relation><relation id="R2"><infon key="score">0.9336</infon><infon key="role1">Disease|MESH:D003924</infon><infon key="role2">Gene|3630</infon><infon key="type">Negative_Correlation</infon></relation></document>
</collection>